Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar.

Published byῬούθ Γιάγκος Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar."— Presentation transcript:

1 Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar peduncle in the first patient were initially interpreted as a clinically silent MS activity. Follow-up MRI 4 weeks later revealed punctate contrast enhancement, compatible with immune reconstitution inflammatory syndrome. Despite repeated intravenous methylprednisolone pulses (black arrowheads), 2 further IRIS episodes (8 and 20 weeks after onset) have been found by serial MRIs (red arrows). IRIS = immune reconstitution inflammatory syndrome; IVMP = IV methylprednisolone. Jin Nakahara et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e559 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Download ppt "Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar."

Similar presentations

Figure EDSS, FS scores, and Modified MSFC scores

Figure EDSS, FS scores, and Modified MSFC scores
Figure 2 ERG amplitude reduction in the follow-up study

Figure 2 ERG amplitude reduction in the follow-up study
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Regional changes in FA values

Figure 1 Regional changes in FA values
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.

Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.
Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.

Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 2 Neurochemical profiles for each neurocognitive trajectory

Figure 2 Neurochemical profiles for each neurocognitive trajectory
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Similar presentations

Ads by Google